Articles related to Psychiatry

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

The colorful fentanyl, known as “rainbow fentanyl,” has been identified in 18 different states and has been found in a variety of forms, including pills, powder, and blocks that resemble sidewalk chalk, according to a press release from the agency. No particular color has been found to have a higher potency through testing. According to the DEA, every shade, shape, and size should be viewed as being exceedingly harmful.

This report on learnings shows that it is crucial to educate primary healthcare professionals on how to spot people who may commit suicide in their later years (eg, using “The 5 Ds” — Deadly methods, Depression, Disease & Disability, Disconnectness, and Development) and how to adopt prevention measures.

Despite having anti-psychotic, anxiolytic, sedative, and hypnotic properties, quetiapine is linked to an increased risk of cardiovascular death and sudden cardiac death when used in conventional doses. For the first time, the current investigation demonstrated that quetiapine taken off-label and in modest doses raises the risk of major adverse cardiovascular events (MACE), stroke, and cardiovascular death.

SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.

This cohort study discovered that depression, anxiety, perceived stress, loneliness, and worry about COVID-19 were prospectively associated with a 1.3- to 1.5-fold increased risk of self-reported post-COVID-19 conditions, as well as an increased risk of daily life impairment related to post-COVID-19 conditions.